Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CRL Charles River Laboratories International Inc
- Stocks
- Healthcare
- NYSE: CRL
Price (delayed)
$144.02
Market cap
$7.07B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.6
Enterprise value
$9.83B
Charles River Laboratories, Inc., is an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted
Highlights
The quick ratio has declined by 20% year-on-year but it is up by 2.2% since the previous quarter
Charles River Laboratories International's debt has increased by 10% QoQ but it has decreased by 3% YoY
The EPS has shrunk by 107% YoY
The net income has dropped by 106% year-on-year
Key stats
What are the main financial stats of CRL
Market
Valuations
Earnings
Shares outstanding
49.12M
Market cap
$7.07B
Enterprise value
$9.83B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.31
Price to sales (P/S)
1.81
EV/EBIT
66.75
EV/EBITDA
18.07
EV/Sales
2.44
Revenue
$4.02B
Gross profit
$1.3B
Operating income
$176.04M
Net income
-$25.29M
EBIT
$147.28M
EBITDA
$544.03M
Free cash flow
$563.24M
Per share
Balance sheet
Liquidity
EPS
-$0.6
EPS diluted
-$0.6
Free cash flow per share
$11.11
Book value per share
$62.46
Revenue per share
$79.38
TBVPS
$79.98
Total assets
$7.58B
Total liabilities
$4.34B
Debt
$2.99B
Equity
$3.19B
Working capital
$455.3M
Debt to equity
0.93
Current ratio
1.43
Quick ratio
0.94
Net debt/EBITDA
5.07
Margins
Efficiency
Dividend
EBITDA margin
13.5%
Gross margin
32.4%
Net margin
-0.6%
Operating margin
4.4%
Return on assets
-0.4%
Return on equity
-0.9%
Return on invested capital
2.6%
Return on capital employed
2.3%
Return on sales
3.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRL stock price
How has the Charles River Laboratories International stock price performed over time
Intraday
0.66%
1 week
24.79%
1 month
44.38%
1 year
-36.95%
YTD
-21.98%
QTD
-4.32%
Financial performance
How have Charles River Laboratories International's revenue and profit performed over time
Revenue
$4.02B
Gross profit
$1.3B
Operating income
$176.04M
Net income
-$25.29M
Gross margin
32.4%
Net margin
-0.6%
The net income has dropped by 106% year-on-year
Charles River Laboratories International's net margin has shrunk by 106% YoY
CRL's operating income has shrunk by 69% YoY and by 23% QoQ
The operating margin has shrunk by 69% YoY and by 21% QoQ
Price vs fundamentals
How does CRL's price correlate with its fundamentals
Growth
What is Charles River Laboratories International's growth rate over time
Valuation
What is Charles River Laboratories International stock price valuation
P/E
N/A
P/B
2.31
P/S
1.81
EV/EBIT
66.75
EV/EBITDA
18.07
EV/Sales
2.44
The EPS has shrunk by 107% YoY
The price to book (P/B) is 50% lower than the 5-year quarterly average of 4.6 and 14% lower than the last 4 quarters average of 2.7
The equity has declined by 12% year-on-year and by 8% since the previous quarter
The P/S is 48% lower than the 5-year quarterly average of 3.5 and 25% lower than the last 4 quarters average of 2.4
CRL's revenue is down by 2.2% year-on-year
Efficiency
How efficient is Charles River Laboratories International business performance
The company's return on assets has shrunk by 107% YoY
The ROE has plunged by 107% YoY
The ROS has shrunk by 78% YoY and by 30% QoQ
The company's return on invested capital has shrunk by 78% YoY and by 32% QoQ
Dividends
What is CRL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRL.
Financial health
How did Charles River Laboratories International financials performed over time
The company's total assets is 75% higher than its total liabilities
The quick ratio has declined by 20% year-on-year but it is up by 2.2% since the previous quarter
Charles River Laboratories International's current ratio has decreased by 18% YoY
Charles River Laboratories International's debt is 7% lower than its equity
Charles River Laboratories International's debt to equity has increased by 18% from the previous quarter and by 9% YoY
The equity has declined by 12% year-on-year and by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.